Adage Capital Partners
AVDL

Adage Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Adage Capital Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-994,738
Closed -$14M – 875
2024
Q2 		$14M Sell
994,738
-916,245
-48% -$14.9M 0.03% 527
2024
Q1 		$32.3M Buy
1,910,983
+1,685,983
+749% +$25.1M 0.06% 333
2023
Q4 		$3.18M Sell
225,000
-1,500,000
-87% -$17.6M 0.01% 723
2023
Q3 		$17.8M Sell
1,725,000
-955,000
-36% -$12.8M 0.04% 424
2023
Q2 		$44.2M Buy
+2,680,000
New +$34.8M 0.1% 212

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Adage Capital Partners's AVDL Position: Q3 2024 in Review

Adage Capital Partners sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 994,738 shares — an estimated $14M sold.

Adage Capital Partners first reported a position in AVDL in Q2 2023 and held it in 5 quarters. The position peaked at $44.2M in Q2 2023. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Adage Capital Partners reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Adage Capital Partners sold 994,738 Avadel Pharmaceuticals shares in Q3 2024, an estimated $14M.
  • Adage Capital Partners first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Adage Capital Partners's Avadel Pharmaceuticals position peaked at $44.2M in Q2 2023.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Adage Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.